Member Info for Doc.Daneeka

Pmjh is right on this last point Spacman. The company hasn't pushed Universal ( I mean how could it when it never communicates about anything . In the absence of other news - and after the disappointment of the last RNS -it's been magnified on this board beyond merit

It remains Tom Wilkinson's project. We should look at it as an industry wide collaborative & free sharing endeavour and stop hoping it will ride to Synairgen's rescue. We all hoped Janssen, AZ and now Sanofi came for Synairgen - the similarities in what UNIVERSAL was trying to do seemed to dovetailed so perfectly with the company’s own work in using biometrics to find patients across a range of viruses. Here was a trial set up to investigate disease commonality across a range of viruses - and here was a company - down the corridor - with a drug with proven efficacy against a range of viruses, trying to find it’s cohort in the same infections.

But the first results, whilst helpful, were largely predictable. Showing that once RIs are confirmed, regardless of the cause - they follow a similar pathway and that age & co-morbities are the principal factors in progression.

Synairgen saw this data - put it next to its own research - and decided, sadly, that the multi-virus game was up.

It's possible that this is not the full story - that something else emerges from all of this and that UNIVERSAL that might help Synairgen in the future - but it seems to me that for now we should let it go.

It wasn’t ever about us. It was about Tom Wilkinson’s wider work and it was a useful and beneficial partnership that made sense at the time of initiation, when Synairgen still had huge ambitions in exactly this space. Ambitions that have now largely been thwarted.

Doc83 Fruits has posted the list before. From memory... Grants - platform trials - gofundme - scratchcards

Good point Ts the intention will UNIVERSAL from the outset was that it would be of benefit to the whole medical science community - with results shared freely. Perhaps this spirit of shared endeavour attracted Sanofi as well as the two founding sponsors.

" Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request "

Thanks again Aether. Not much love for your good work - but appreciated nonetheless.

Confirms that the trial is ongoing - as I said it was - and that Sanofi has not taken over to add a drug phase ( ie SNG) as was preposterously suggested.

There will be a new protocol for the sub trial - which will explain how they're running it and whether they're changing the inclusion criteria to focus on ARDS

Try switching it off and on again Gunto

Wow Aether - well done. "Detection of Bordetella pertussis signal "

There's still time for Simon Shaw's reassurance of 6 weeks ago to come good. Surely even he wouldn't use such language without an expectation that a funding deal was close to completion. It won't be free of course ( despite Fruits' dream of a non-dilutory money tree) but it's the only hope. If this hope has been thwarted, is it possible TFG would let them sit on these salaries until the candle burns down ?

nice one brand. copd even calls it triple therapy - to which the new treatments will be added. quad or *****uple therapy if you like. patients will have the existing triple drug inhalers and the 2 newly approved longterm maintenance therapeutics, both of which have proven efficacy results in the mid 30%s. a monoconal and an inhaled phosphodiesterase inhibitor. you could add sng on too i guess .. 5 years and £60m of trialing down the line maybe.

facetiuous maybe. fruits will be on in a moment to tell us how big the market place is - but if your drug isn't better and isn't cheaper it's a hard argument to make to even start that process ( which is the difficult reality synairgen have recently accepted )

precision medicine is the game - as our friends are always telling us - but what this means in almost every sphere - is mabs and mrna. mrna saved the day with covid ( although the virus weakened anyway ) and mabs are now being engineered to target every other respiratory disease, while mrna will be the first defence in any future outbreaks.

ok thinshins some fair points. i'll filter pmjh and try not to respond to any of the sanofi az universal discussion. even though i think it's a cynical diversionary tactic to quieten the board as the wait for news goes on. i don't think there's any chance it's related to us - even if something new is happening with universal - which can't have completed recruitment of 1k patients if the company said they had 500 6 weeks ago and which as far as we know was not employing any clever assays to help id a patient cohort. bickering is unseemly though as you say so i'll leave it there. trust me though - there's onl;y one reality , and that's the one rm described at the end of june. the rest of it is pseudo-science ******ios

Ah well done Gunto. Pat pat. Good dog

I never mentioned him at all while he left us alone. Not for 22 months of that 2 years as he hid his face in shame. Goodness only knows what he's doing down here now - peddling irrelevancies and saying he can see possible connections where none can possibly exist. He was right once about ACTIV2 - and that was pretty big - but every other thing he's written and all of his little handmaidens have ferried down to planet earth - has been garbage. His links are vapour trials that blow away as quickly as the wind finds them. He's a search engine - nothing more. This current line about Sanofi and AZ and UNIVERSAL - all of it is junk, and half of it has been posted here months ago. He tells us the trial is complete - when Synairgen said 500 of 1000 patients had been recruited in June ( 2 years to collect 500 but they found the rest in 6 weeks ) He suggests possible connections that might lead to a platform trial - or Sanofi adding SNG to UNIVERSAL - when we've already seen the first batch of data and Synairgen has said it is not pursuing the trials that UNIVERSAL might have found patients for.

It's your choice what and who you believe. I've been right about this company more often than any of the fanboys and I’ll continue to post the reality, whenever they trot out their delusional fantasies.

I hope this is not the end for SNG but there is no win from here for LTHs. All that matters now is how much value a 3rd party attaches to the IP

Pmjh is a first class ferret, but he has no idea how to join any of the dots or what they mean. This ongoing daily posting frenzy has nothing to do with SNG. We've had years of breadcrumb trails - the last 2 mercifully without his input - and they have all led nowhere. There is nothing sneakly or clever going on in relation to UNIVERSAL, and Synairgen is not about to announce something dramatic. We saw the first results from the trial and they were not significant enough to inform the results RNS in a critical way. Indeed, Synairgen looked at them and then announced it had abandoned the multi viral pathway ( which UNIVERSAL was meant to provide key biometric data for )

We're waiting for an MV announcement. Hopefully someone is gonna pay for the trial.

Astrazeneca has an IL-33 inhibting candidate. It's called Tozorakimab

https://www.nature.com/articles/s41598-023-36642-y#Abs1

Another Fruits classic to start the week. " I must admit I'm glad the company are playing their cards close to their chest. I wouldn't want genuine progress disrupted "

That's just not true Fruits. Regulators don't control the trial you run, but they might suggest changes. If you can show that Synairgen ever had sample collection in the protocol I'll give way, but they didn't.

100s of trials were collecting samples throughout the pandemic - so that doesn't fly either.

"SPRINTER could review some potential inflammatory markers in the subjects, Fish says. But Dr Phillip Monk, chief scientific officer at Synairgen, says SPRINTER investigators have not been asked to measure such markers. "

Gunto " Aside from Andybe4, does anyone else recall this article? https://www.clinicaltrialsarena.com/features/timing-of-synairgen-phase-iii-nebulised-covid-19-treatment-remains-a-challenge/ "

thanks gunto an interesting trip down memory lane - written a couple of months b4 Sprinter landed - when the Mcap was $551.18m.

The most important point in hindsight is the part that deal with patient ID and the collection of samples

" If SPRINTER identifies specific patients, such as those with defects in interferon-signaling pathways, SNG001 could become a treatment with a specific subset of patients, Jackson adds. This includes individuals with rare genetic mutations in different pathways, Duffy says.

Another target population could be individuals with high autoantibody counts of autoantibodies against type I interferons, which increase with age and have been linked to severe cases of COVID-19,

SPRINTER could review some potential inflammatory markers in the subjects, Fish says. But Dr Phillip Monk, chief scientific officer at Synairgen, says SPRINTER investigators have not been asked to measure such markers. "

Whatever the difficulties of harvesting samples at the height of the pandemic - to not even attempt to do it, to throw all of that golden data in the clinical waste bin, is the main reason why they've struggled and ultimately failed to find the target population in the 2 and a half years since.

proactive " richard - the last time we met you talked about your drug's potential as a multi viral variant agnostic therapeutic, and the ground-breaking work the company was doing to identify the cohort of hospitalised patients, across a range of repiratory infections, that would benefit from sng. was that just bull**** ? "

rm " i'm sorry - the line just dropped - what were you saying .... hold on... you'll have to excuse me .. i have an important call i must take ? "

Gunto posting on a Saturday to complain about people posting on a Saturday hahaha

We know that Pmjh. 21 days. Doc83 posted it months ago. Basic stuff.

Thanks for the reminder that the AGM is now at least 2 months late :)